Tramadol News and Research

RSS
Labopharm amends debt facility agreement with Hercules Technology Growth Capital

Labopharm amends debt facility agreement with Hercules Technology Growth Capital

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

TheraQuest launches new analgesic product pipeline

TheraQuest launches new analgesic product pipeline

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

Study confirms Azilect as a selective MAO-B inhibitor

Study confirms Azilect as a selective MAO-B inhibitor

Labopharm completes joint venture with Gruppo Angelini

Labopharm completes joint venture with Gruppo Angelini

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail reports 27% increase in first-quarter 2010 total revenues

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Labopharm, Gruppo Angelini sign agreement to commercialize OLEPTRO in the U.S.

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Cipher Pharmaceuticals' first-quarter total revenue up 52%

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm launches INTELLITAB abuse and misuse-deterrent technology platform

Labopharm: Investment report

Labopharm: Investment report

Nippon Shinyaku to market and sell Labopharm's once-daily tramadol in Japan

Nippon Shinyaku to market and sell Labopharm's once-daily tramadol in Japan

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Cipher Pharmaceuticals' enrollment milestone in CIP-ISOTRETINOIN study triggers $2.0M milestone payment

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Health Canada accepts Cipher Pharmaceuticals' NDS for CIP-TRAMADOL ER

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Biovail reports 33% increase in total revenues for fourth-quarter 2009

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Sales revenue from Labopharm's once-daily tramadol increases to $4.7M for fourth-quarter fiscal 2009

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009

Par Pharmaceutical reports total revenues of $1,193.2 million for 2009